Patients with hematologic diseases who are being treated with therapy drugs, or receive radiation therapy or blood transfusions may develop a host of potentially fatal infectious and noninfectious pulmonary complications [1]. The increased complexity of multimodality and high-dose treatment regimens with the intended benefit of augmented antineoplastic efficacy and prolonged disease-free survival, the use of a panel of novel drugs to treat malignant and nonmalignant hematologic conditions (e.g., azacytidine, bortezomib, cladribine, dasatinib, fludarabine, imatinib, lenalidomide, rituximab, and thalidomide), total body irradiation (TBI) and hematopietic stem cell transplantation (HSCT) have increased the incidence of severe sometimes life-threatening pulmonary complications.
CITATION STYLE
Camus, P. (2011). Pleuropulmonary Changes Induced by Drugs in Patients with Hematologic Diseases. In Pulmonary Involvement in Patients with Hematological Malignancies (pp. 387–423). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-15742-4_31
Mendeley helps you to discover research relevant for your work.